Sapropterin

Sapropterin is the pharmaceutical name for 6R-tetrahydrobiopterin, or BH4, the active cofactor of the three aromatic amino acid hydroxylase enzymes ^[1]. It is manufactured as sapropterin dihydrochloride, a stabilized salt of a molecule the body normally makes itself, and is classified as an enzyme cofactor and orphan drug ^[1]. BH4 is synthesized in many tissues from guanosine triphosphate through a multistep pathway and is regenerated after each hydroxylation reaction by the enzyme dihydropteridine reductase ^[1].

Its principal use is in phenylketonuria (PKU), an inherited disorder in which mutations in phenylalanine hydroxylase impair the conversion of phenylalanine to tyrosine, allowing phenylalanine to build up to levels that can harm the developing brain ^[3]. In patients whose enzyme retains some function, sapropterin taken alongside a phenylalanine-restricted diet can lower blood phenylalanine and increase dietary tolerance ^[1][4]. It is also indicated for tetrahydrobiopterin deficiency caused by defects in BH4 synthesis or recycling. Importantly, at least half of people with PKU show little or no response, so a loading test is used to identify likely responders ^[2][3].

Sapropterin was approved by the US Food and Drug Administration in 2007 and by the European Medicines Agency in 2008, initially as tablets and later as a powder for oral solution, and is marketed as Kuvan and elsewhere as Biopten ^[1]. Its introduction marked the first drug therapy for PKU, a condition previously managed by diet alone, and expert reviews have emphasized both its value for responders and the significant gaps in predicting who will benefit ^[2].

The drug is taken orally as tablets or dissolved powder, and some studies suggest that dividing the daily amount may improve phenylalanine tolerance compared with a single dose ^[4]. Large genotype databases have improved the ability to predict both disease severity and tetrahydrobiopterin responsiveness from a patient's specific phenylalanine hydroxylase variants ^[3].

Sapropterin is generally well tolerated. The most commonly reported effects include headache and upper respiratory or nasal symptoms, with gastrointestinal complaints such as diarrhea and vomiting occurring less often ^[1]. Because it is a natural cofactor rather than a foreign chemical, its safety profile is favorable, though it remains an expensive specialty medication ^[1].

As a prescription drug it should only be used under medical supervision. Reported effects include headache, runny nose, throat irritation, diarrhea, and stomach upset; it can rarely trigger hypersensitivity reactions. It interacts with drugs affecting nitric oxide and with other medications, so a clinician needs to manage it.

Three interactions are documented, and only one of them is common. Drugs that inhibit dihydrofolate reductase, methotrexate above all, block the salvage pathway that regenerates tetrahydrobiopterin; less active cofactor is available and blood phenylalanine can climb back up despite treatment. Trimethoprim and pyrimethamine act on the same enzyme.

Levodopa is the safety signal. Across a decade of post-marketing surveillance in a non-phenylketonuria indication, seizures, worsened seizures, overstimulation and irritability were reported in patients with underlying neurological disease taking both, presumably because supplying the cofactor for tyrosine hydroxylase adds to an already loaded dopamine pathway.

Sapropterin is also the cofactor for nitric oxide synthase and can lower blood pressure slightly. Adding a PDE5 inhibitor is expected to be additive, though the combination has been examined only in animals; in humans the interaction remains theoretical.

Checking a whole stack? Run it through interactions + stacks.